Navigation Links
Propofol poses low risk in pediatric imaging studies, but risk increases with anesthesia duration
Date:6/9/2010

Washington, DCA new study finds that propofol, a well-known anesthesia medication, has a low occurrence of adverse events for children undergoing research-driven imaging studies. The study, led by a pediatric anesthesiologist now at Children's National Medical Center, showed a low incidence of adverse events and no long term complications when propofol was used to sedate children for imaging studies that require them to be still for long periods of time.

Lead author Zena Quezado, MD, director of the Pain Neurobiology Laboratory at the Sheikh Zayed Institute for Pediatric Surgical Innovation, also found, however, that propofol, a commonly used anesthetic, does show an increased risk for respiratory, cardiovascular, and other side effects if anesthesia is administered over a long period of time or if the child has other complicating factors, including some systemic disease or an airway abnormality. It is also the first imaging study to show an increase in risk to the child with each 30 minute increment a child was under anesthesia.

The findings will help Institutional Review Boards and parents, who are dealing with the ethics debate around research involving children, evaluate the risk-benefit ratio of proposed studies, particularly those involving prolonged imaging studies.

"Getting a child to remain still in an uncomfortable environment during a medical imaging procedure, such an MRI or CT scan, where bodily movement undermines the procedure's quality, is a near impossible task, which is why anesthesia is commonly used," Dr. Quezado said. "We know that propofol can be safely administered in pediatric research studies by well-trained anesthesiologists who are prepared to anticipate and respond to all events, which minimizes the risk of adverse issues. We are applying the findings of this research immediately in our own work, and will help others ensure that every study involving children is safe, ethical and effective."

The study reviews 1,480 propofol anesthetics in 607 children over an eight year period at the NIH's Clinical Research Center and appears in the June 7 issue of Archives of Pediatric and Adolescent Medicine. A total of 98 notable events were observed in 63 patients. Only one event led to an escalation of planned therapy. No events led to prolonged hospitalization.

The increased risk related to severity of systemic disease is in concert with clinical studies that show increasingly severe systemic disease is associated with an increased risk for anesthesia related complications, while patients with airway abnormalities are predisposed to airway obstruction.

Dr. Quezado recently joined Children's National Medical Center from NIH. She plays a leading role in the Sheikh Zayed Institute's Pain Medicine Initiative, which aims to improve surgical outcomes through the reduction and elimination of pain. The Institute creates unprecedented opportunities for cross-disciplinary collaborations among leaders from a broad spectrum of sciences, united under one roof to expedite the research into development of more effective treatments.

Team science is often talked about but rarely achieved," Quezado said. "The Institute's balance between clinical and research work and its robust support of truly collaborative partnerships among doctors and scientists, provides tremendous translational research opportunities. That allows us to advance research more quickly and build upon studies like this one, in our ultimate quest to eliminate pain and improve outcomes for children."


'/>"/>

Contact: Emily Dammeyer
edammeye@cnmc.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related biology news :

1. DNA barcoding exposes fake ferns in international plant trade
2. Linheng Li proposes novel theory for mammalian stem cell regulation
3. New, virulent strain of MRSA poses renewed antibiotic resistance concerns
4. Type 2 diabetes gene predisposes children to obesity
5. Treatment not testicular cancer poses greatest risk to survivors long-term health
6. Daily consumption of cannabis predisposes to the appearance of psychosis and schizophrenia
7. New asthma research opposes current drug treatment, says UH prof
8. Research exposes the risk to infants from the chemicals used in liquid medicines
9. Research exposes new target for malaria drugs
10. Baker Institute report proposes strategies to ensure global energy security
11. Use of nanomaterials in food packaging poses regulatory challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016 Valencell , the leading ... has seen a third consecutive year of triple digit ... in 2016 with a 360 percent increase in companies ... increase was driven by sales of its wrist and ... in its technology for hearables for fitness and healthcare ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... DIEGO , Dec. 8, 2016  Biotheranostics ... demonstrating the role of the Breast Cancer Index ... ER+ breast cancer are most at-risk for disease ... Data include results from three studies advancing the ... information related to tumor biology and inform decisions ...
(Date:12/8/2016)... 2016 Oxford Gene ... seine Palette an anpassbaren SureSeq™ NGS-Panels mit dem ... das ein schnelles und kostengünstiges Studium der Varianten ... eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) ... kleinen Panel und ermöglicht eine individuelle Anpassung durch ...
(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... ... as finalists in the World Technology Awards. uBiome is one of just six ... across all categories. , In addition to uBiome, companies nominated as finalists in ...
(Date:12/8/2016)... 2016 Savannah River Remediation LLC group ... NewTechBio,s NT-MAX Lake & Pond Sludge and ... in conjunction with Hexa Armor/ Rhombo cover manufactured ... Pollutant Discharge Elimination System requirements. The ... history of elevated pH levels, above 8.5, especially ...
Breaking Biology Technology: